GSK has recently filed multiple lawsuits against Moderna over patent infringements related to mRNA vaccine technology. The company claims that Moderna's vaccines for COVID and RSV are infringing upon their patents. In addition to GSK, Northwestern University too has claimed patent infringement by Moderna, for its Spikevax vaccine. In the financial markets, Moderna's stock has decreased by 20% within a month. However, Moderna remains of interest to Hedge funds and is seen as potentially promising.
This litigation storm coincides with Moderna securing a contract with the U.S. government where it has been awarded $176 million to develop an mRNA-based bird flu pandemic vaccine. There's further optimism around Moderna’s potential mRNA solid tumour vaccine which has shown early promise, and its mRNA-based mpox vaccine that demonstrated effectiveness in early testing. Yet, some concerns persist over the side-effects linked to mRNA vaccines and recommendations to opt for Novavax's vaccine instead.
Moderna MRNA News Analytics from Wed, 07 Feb 2024 08:00:00 GMT to Sat, 19 Oct 2024 15:19:13 GMT - Rating -2 - Innovation 7 - Information 8 - Rumor -4
